San Francisco, California (November 12, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2019 and provided updates on its programs. For the third quarter 2019, KindredBio reported net product revenues of $1.1 million and a net loss […]
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Tuesday, November 12, 2019. San Francisco, California (October 28, 2019) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2019 financial results on November […]
Tuesday, November 12, 2019 Time of Event: 4:30 p.m. Eastern time/1:30 p.m. Pacific time Telephone Dial in: toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally Conference ID: 8153966 For more information about this event, please see the press release.
Mirataz would be the first and only medication approved in the EU to treat cats experiencing poor appetite and weight loss resulting from chronic medical conditions. San Francisco, California (October 10, 2019) – Kindred Biosciences, Inc. (Nasdaq: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that the […]
San Francisco, California (October 2, 2019) – Kindred Biosciences, Inc. (Nasdaq: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the closing of a $50 million senior secured debt facility with investment affiliates managed by Solar Capital Partners, LLC. “We are pleased to have further strengthened our balance […]
San Francisco, (September 10, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company developing novel drugs and biologics, today announced that it has been selected by the National Cancer Institute (NCI) as one of three contractors in response to the solicitation for the PREVENT Cancer Preclinical Drug Development Program (PREVENT): Current Good Manufacturing […]
Tuesday, September 10, 2019 Location: Lotte New York Palace Hotel Presentation time: 8:20-8:45a.m. ET in Adams, 4th Fl Company Attendee: CEO Richard Chin Webcast URL: Click here For more information about this event, please see the press release.
Thursday, September 12, 2019 Location: Parker NY Company Attendee: CEO Richard Chin For more information about this event, please see the press release.
Wednesday, October 2, 2019 Location: InterContinental New York Barclay Presentation time: 8:20–8:50 AM ET in (5) Grand Ballroom 2 Company Attendee: President and COO Denise Bevers Webcast URL: Click here For more information about this event, please see the press release.
San Francisco, California (August 28, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 10, the Lake Street Best Ideas Growth Conference on September 12, and the Cantor Global Healthcare Conference on October 2, in […]
-0.20 (-2.42%)
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
